Anti-Nuclear Antibodies in Daily Clinical Practice: Prevalence in Primary, Secondary, and Tertiary Care
Figure 3
Anti-ENA/dsDNA reactivity stratified for primary, secondary, and tertiary care. The relative prevalence (%) of anti-ENA/dsDNA reactivity in ANA positive sera is presented for primary, secondary, and tertiary care (a). The relative prevalence (%) of 1 or more specificities (b) and type of specificities (c) is displayed in primary (black bars), secondary (grey bars), and tertiary care (white bars). Notably, in primary and secondary care anti-dsDNA antibodies were detected by FEIA, while in tertiary care CLIFT was the method of choice.
